Skip to main content

Table 1 Comparison of demographic, clinical, and laboratory results in PMR patients with or without response to 12.5 mg daily of prednisone

From: The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity

FEATURE

RESPONDERS

NON RESPONDERS

p

Number

47 (78.3%)

13 (21.7%)

 

Gender (women/men)

31/16

4/9

0.05

Age (years)

71.3 ± 7.1

71.5 ± 7.9

0.95

Weight (kg)

67.4 ± 11.4

78.5 ± 13.9

0.004

Disease duration (days)

90 (12-720)

86 (24-210)

0.32

Morning stiffness (minutes)

100.7 ± 85.9

89.0 ± 52.2

0.69

Fatigue

26 (55.3%)

10 (76.9%)

0.28

Fever

10 (21.3%)

3 (30%)

0.81

Weight loss

16 (34%)

2 (15.4%)

0.34

Peripheral arthritis

13 (27.7%)

4 (30.8%)

0.89

Carpal tunnel syndrome

16 (34.0%)

2 (15.4%)

0.34

RS3PE

8 (17.0%)

2 (15.4%)

0.78

Tenosynovitis

4 (8.5%)

1 (7.7%)

0.64

ESR (mm/h)

63.8 ± 25.8

62.5 ± 22.4

0.88

CRP (mg/L)

30 (1.5-180)

30 (2.5-247)

0.96